Drug intelligence / Profile preview

SIR-T IL13Ra2

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intratumoral, Intrathecal

Overview

SIR-T IL13Ra2 is a preclinical-stage cell therapy developed by Angeles Therapeutics. It utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which is designed to engineer T cells to recognize and eliminate cells expressing Interleukin-13 receptor subunit alpha-2 (IL13Ra2). IL13Ra2 is a tumor-associated antigen frequently overexpressed in various solid tumors, most notably glioblastoma multiforme. The SIR-T architecture aims to provide enhanced signaling and persistence compared to traditional CAR-T designs, potentially improving efficacy in the immunosuppressive microenvironment of solid tumors.

Other names: SIR-T IL13Ra2

Targets

IL13RA1 (Interleukin-13 receptor subunit alpha-1)IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on SIR-T IL13Ra2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T IL13Ra2.

Explore the full profile